NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Coya Therapeutics, Inc. (COYA) Stock Analysis

Coya Therapeutics, Inc. (COYA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

COYA

$4.14

−$0.07 (−1.66%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare COYA with… →

COYA Key Statistics

As of Oct 21, 2026
Trading
Open
$4.25
Previous Close
$4.21
Day's Range
4.10–4.29
52-Week Range
3.71–7.55
Volume
94.35K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.58
Valuation
Market Cap
$97.12M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
12.11
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.07
Financials (FY)
Revenue (FY)
$7.95M+123.57%
Net Income (FY)
−$21.23M
Profit marginThe share of revenue left as profit after all costs and taxes.
−270.22%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
23.46M
1-Year Return
−36.01%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
135.80K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, COYA closed at $4.14, −36.01% over 1 year.

Coya Therapeutics, Inc. (COYA) has a market capitalization of $97.12M.

In fiscal 2025, COYA reported revenue of $7.95M.

COYA Stock Return by Calendar Year

Coya Therapeutics, Inc. (COYA) return since Dec 2022: what $10,000 became

1 year
$10,000 $6,399
−36.01%
3 years
$10,000 $8,347
−16.53%
Since Dec 2022
$10,000 $9,059
−9.41%

If you had invested $10,000 in Coya Therapeutics, Inc. (COYA) at the close on December 29, 2022, the earliest close on record here, it would have been worth $9,059 at the close on October 21, 2026: −9.41% in total, −2.56% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−28.62%
2025+1.22%
2024−22.67%
2023+56.40%
2022 (partial year)+3.68%

As of October 21, 2026.

COYA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$7.95M−$21.23M−267.1%
2024$3.55M−$14.88M−418.7%
2023$6.00M−$7.99M−133.1%
2022$0.00−$12.24M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$7.95M—−$22.56M−$21.23M−267.1%
2024$3.55M—−$17.25M−$14.88M−418.7%
2023$6.00M—−$7.90M−$7.99M−133.1%
2022$0.00—−$9.81M−$12.24M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

COYA Valuation vs Biotechnology Median

Median of 608 stocks
MetricCOYABiotechnology medianvs median
P/S ratio12.1113.309% below
Profit margin−270.22%−38.31%231.9 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Coya Therapeutics, Inc. (COYA) carries a market capitalisation of $97.12M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 8 employees.

Over the past 52 weeks the price has ranged from $3.71 to $7.55. The most recent close on file for COYA is $4.14, dated October 21, 2026. That is −$0.07 (−1.66%) against the previous close. The latest close sits 11.59% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $7.95M. That is +123.57% against the prior fiscal year, when revenue was $3.55M. The same year closed with a net loss of $21.23M. Profit margin runs at −270.22%. That is 231.9 percentage points below the Biotechnology median of −38.31%. Trailing earnings per share are −1.07.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $7.95M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 12.11 times revenue. On price-to-sales that is 8.93% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −36.01%. Across 3 years the annualized return works out at −5.85%. Beta against the wider market is reported at 0.58. Daily returns over the trailing 3 years annualize to a volatility of 70.13%.

Growth & Income

The record shows no dividend for COYA.

2026 is still running; the total return is −28.62% year to date. Across the complete calendar years on file, 2023 returned +56.40% and 2024 returned −22.67%. Of the 3 complete calendar years on file, 2 finished higher.

Peer Comparison

Coya Therapeutics, Inc. (COYA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Coya Therapeutics, Inc. COYA $97.12M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Coya Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Coya Therapeutics, Inc.

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.

Visit website →